You are viewing: New Zealand Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The New Zealand Leukapheresis Market was valued at $0.6 Million in 2026 and projected to reach to $0.91 Million by 2031, representing a compound annual growth rate of 8.8%. New Zealand's leukapheresis market is poised for steady growth through 2031, driven by rising prevalence of hematologic malignancies and expanding adoption of cell-based immunotherapies.

New Zealand Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

New Zealand Leukapheresis Market Trends and Insights

  • The market in New Zealand is expected to expand to USD 0.91 million by 2031, reflecting a compound annual growth rate of 8.8%.
  • This growth trajectory in New Zealand is driven by increasing adoption of cell therapy technologies and rising prevalence of hematologic malignancies requiring advanced therapeutic interventions. New Zealand's healthcare infrastructure and regulatory environment support the integration of leukapheresis procedures within clinical practice.
  • The market in New Zealand benefits from growing investment in oncology and immunotherapy treatments, alongside enhanced patient access to specialized medical centers.
  • Between 2026 and 2031, New Zealand is anticipated to see steady demand for leukapheresis equipment and services as healthcare providers expand their therapeutic capabilities..

Key Market Statistics

  • CAGR (2026-2031) 8.8% CAGR
  • Market Size, 2026 ~USD 0.6 Million
  • Forecast, 2031 ~USD 0.91 Million
  • Country New Zealand

New Zealand Leukapheresis Market Overview

Market Valuation :

New Zealand's leukapheresis market is valued at USD 0.6 million in 2026, with projected growth to USD 0.91 million by 2031, representing a robust 8.8% CAGR aligned with global expansion trends.

Cell Therapy Adoption :

New Zealand is experiencing increased adoption of advanced cell therapy technologies, driving demand for leukapheresis procedures as healthcare providers expand treatment capabilities for hematologic malignancies and immunotherapies.

Regional Growth Dynamics :

As part of the Asia Pacific healthcare landscape, New Zealand benefits from regional investments in oncology infrastructure and CAR-T cell therapy development, positioning it as a growing market for apheresis technologies.

Healthcare Infrastructure :

New Zealand's advanced healthcare system and increasing prevalence of blood disorders support the expansion of leukapheresis services, with growing patient access to specialized treatment centers and clinical facilities.

New Zealand Leukapheresis Market Dynamics

  • Healthcare providers are increasingly investing in apheresis equipment and trained personnel to meet growing patient demand for CAR-T cell therapy and other advanced treatments.
  • The market benefits from New Zealand's robust healthcare infrastructure and government support for innovative cancer treatments. Key growth catalysts include increasing clinical trial activities, expanding reimbursement pathways for cell therapies, and growing awareness among oncologists and hematologists about leukapheresis benefits.
  • Strategic partnerships between New Zealand healthcare institutions and international biotech companies are expected to accelerate market penetration.
  • By 2031, the market will likely see enhanced service availability across major metropolitan areas and improved patient outcomes through advanced apheresis technologies..

Related Ecosystem

Key Takeaways

  • New Zealand's leukapheresis market is valued at USD 0.6 million in 2026 and is projected to reach USD 0.91 million by 2031.
  • New Zealand demonstrates a steady 8.8% CAGR, reflecting growing adoption of cell therapy and immunotherapy in the region.
  • New Zealand's healthcare infrastructure increasingly supports specialized leukapheresis procedures for hematologic malignancies.
  • New Zealand's market growth is supported by rising investment in oncology centers and enhanced patient access to advanced therapeutic technologies.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

New Zealand Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Manufacturers of apheresis equipment and leukapheresis systems need New Zealand-specific market data to evaluate market entry opportunities, competitive positioning, and revenue forecasts for product launches and distribution partnerships.
  • Pharmaceutical & Biotech Companies : Cell therapy and immunotherapy developers require insights into New Zealand's leukapheresis adoption rates and patient populations to support clinical trial planning, market access strategies, and commercial viability assessments.
  • Healthcare Providers & Hospitals : New Zealand oncology centers and hematology departments need market intelligence to justify capital investments in leukapheresis infrastructure, understand patient demand trends, and plan service expansion strategies.
  • Healthcare Investors & Consultants : Investment firms and management consultants analyzing New Zealand's healthcare sector require detailed market data to identify growth opportunities, assess portfolio companies, and guide strategic healthcare investments.
  • Government & Regulatory Bodies : New Zealand health authorities and policy makers need market insights to inform reimbursement decisions, healthcare infrastructure planning, and regulatory frameworks supporting advanced cell therapy adoption and patient access.

Key Companies in the New Zealand Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Market-Specific Sizing : Access precise valuation data for New Zealand's leukapheresis market with detailed 2026-2031 forecasts, enabling accurate investment planning and resource allocation decisions specific to this emerging market segment.
  • Competitive Landscape Intelligence : Understand New Zealand's unique competitive dynamics, key healthcare providers offering leukapheresis services, and market entry strategies tailored to the country's regulatory environment and healthcare system structure.
  • Growth Driver Analysis : Identify specific factors driving 8.8% CAGR in New Zealand including cell therapy adoption rates, prevalence trends, reimbursement policies, and infrastructure investments critical for strategic planning.
  • Regional Context : Gain insights into how New Zealand's market fits within the broader Asia Pacific leukapheresis landscape, including comparative growth rates and regional collaboration opportunities for market expansion.
  • Investment Decision Support : Make informed decisions about market entry, partnership development, or product launches in New Zealand with comprehensive data on patient populations, clinical adoption rates, and revenue potential through 2031.

Frequently asked questions

What is the current market size of leukapheresis in New Zealand?

New Zealand's leukapheresis market was valued at USD 0.6 million in 2026.

What is the projected market size for leukapheresis in New Zealand by 2031?

New Zealand's leukapheresis market is forecast to reach USD 0.91 million by 2031.

What is the CAGR for the leukapheresis market in New Zealand?

New Zealand's leukapheresis market is expected to grow at a compound annual growth rate of 8.8% from 2026 to 2031.

What factors are driving growth in New Zealand's leukapheresis market?

Growth in New Zealand's leukapheresis market is driven by increased adoption of cell therapy technologies, rising prevalence of hematologic malignancies, and expanding investment in oncology infrastructure.

How does New Zealand's leukapheresis market compare to the Asia Pacific region?

New Zealand represents a specialized segment within the broader Asia Pacific leukapheresis market, with its own distinct regulatory environment and healthcare infrastructure supporting steady market expansion.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status